Undiagnosed RA During the Pandemic
EurekAlert!
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
News
SLE T2T - Lupus Low Disease Activity State Predicts Outcomes
Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.
2022 CDC Clinical Practice Guideline on Opioid Prescribing
CDC
The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.
ACR Promotes CME on Lupus Clinical Trials Racial Disparities
ACR
The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p
Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?
Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA).
Lack of Gender Equity in Academic Rheumatology
Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.
Excessive Alcohol-Related Deaths in US Adults
Alcohol consumption is a leading preventable cause of death in the U.S. A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49.
EMA Crack Down on JAK Inhibitors
The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Growing Confidence in Biosimilars?
MediaSource
Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends
Infection: a Leading Cause of Death in Lupus
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Update to Axial Spondyloarthritis Guidance
MedPage Today
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
